Analysts have identified an area of European biopharma in which 2014 was a middling year: M&A. The data show that while deals involving U.S. biotechs hit new highs, the renewed optimism in Europe has yet to translate into the signing of checks.
Wright Medical Group had expected to complete its acquisition of Tornier during the first half of this year. But now that is a "best case scenario," according to a statement from the company. The Federal Trade Commission has extended the waiting period until the deal close in order to give Tornier time to deal with the agency's concerns about its lower extremity products.
Wound-care outfit Alliqua Medical shelled out $30.4 million for ultrasound therapy company Celleration, broadening its portfolio and gaining ground in regenerative medicine.
Secretary of Health and Human Services Sylvia Burwell, incoming head of the federal Centers for Medicare & Medicaid Services, last week set explicit goals toward paying providers based on quality and not quantity, as the agency aims to put the fee-for-service model to sleep--permanently.
In the wake of the closure of Medtronic's mega, nearly $50 billion purchase of Covidien, CEO Omar Ishrak announced that the company will give $10 to charity for every email he receives from an employee containing reflections on the company's mission to restore health, alleviate pain and extend life.
Fast-expanding CRO genae is buying into clinical trial technology, acquiring a company that focuses on electronic data capture.
Mylan will pay $750 million in cash to buy the women's healthcare businesses from India's Famy Care, placing it as the top seller of contraceptives in emerging markets.
Ranbaxy Laboratories may soon be selling its generic minocycline antibacterial drug to Torrent Pharmaceuticals as a condition for U.S. approval for its merger with Sun Pharmaceuticals.
Valeant has finally made a significant M&A move after its failed pursuit of Allergan, and bankrupt Dendreon has finally found a way to unload cancer vaccine Provenge. And they're one and the same.
Ever since Pershing Square's William Ackman snapped up $1.5 billion worth of Zoetis shares in November, the animal health company has been doing everything it can to stave off a takeover attempt. Ackman, after all, is famous for pressuring companies to put themselves up for sale--most recently trying to push Allergan into a merger with Valeant.